Skip to main content
OpenTrials
Completed

NCT Number: NCT05191498

Intratumoral Holmium Microspheres Brachytherapy for Patients With Pancreatic Cancer

This is a feasibility study in which patients with pancreatic cancer are treated with intratumoral holmium microsphere injections.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Radboud University Medical Centre

Nijmegen, Gelderland, 6525GA, Netherlands

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female or male aged 18 years and over.
  • Diagnosis of primary (borderline) resectable pancreatic cancer by Dutch Pancreatic Cancer Group (DPCG) guidelines:

i. 1o-90o contact between tumor and the superior mesenteric artery, celiac axis or common hepatic artery. Or; ii. 90o-270o contact between tumor and superior mesenteric vein or portal vein, without occlusion.

iii. The discussion on resectability has to be made in consensus at multidisciplinary meetings/discussions and may overrule the above criteria (i, ii).

  • Patient is deemed eligible for surgical resection of the pancreatic cancer, however, during open surgery a more advanced disease than initially anticipated is found and resection is no longer feasible.
  • Life expectancy of 12 weeks or longer.
  • World Health Organisation (WHO) Performance status 0-1.
  • One or more measurable lesions of at least 10 mm in the longest diameter by spiral CT or MRI according to the Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 criteria.
  • Negative pregnancy test for women of childbearing potential.

Exclusion criteria

  • Radiation therapy within the last 4 weeks before the start of study therapy.
  • Calcifications in the pancreas or tumour that are highly expected to obstruct the needle tract
  • Any unresolved toxicity greater than National Cancer Institute (NCI), Common Terminology Criteria for Adverse Events (CTCAE version 4.0) grade 2 from previous anti-cancer therapy.
  • Leukocytes < 4.0 109/l and/or platelet count < 100 109/l.
  • Significant cardiac event (e.g. myocardial infarction, superior vena cava (SVC) syndrome, New York Heart Association (NYHA) classification of heart disease ≥2 within 3 months before entry, or presence of cardiac disease that in the opinion of the Investigator increases the risk of ventricular arrhythmia.
  • Patient is deemed ineligible for implantation of 166Ho by an expert panel (surgeon, nuclear medicine physician and researcher) due to tumour anatomy or nearby structures.
  • Pregnancy or breast feeding (women of child-bearing potential).
  • Patients suffering from psychic disorders that make a comprehensive judgement impossible, such as psychosis, hallucinations and/or depression.
  • Patients who are declared incompetent.

Treatment and study plan

QuiremSpheres®

Device

Intratumoral injection of QuiremSpheres® up to a dose of 150 Gy.

Primary outcomes

  1. Average tumour dose by SPECT imaging

    Time frame: At 1 week after intervention

    To establish the feasibility of intratumoral implantation of QuiremSpheres® by evaluating the average tumour absorbed dose in Gy calculated on SPECT.

Secondary outcomes

  1. Microsphere distribution by MRI

    Time frame: At 1 week after intervention

    Microsphere distribution in analysed using MRI to evaluate tumour absorbed and non-target absorbed dose.

  2. Microsphere distribution by CT

    Time frame: At 1 week after intervention

    Microsphere distribution in analysed using CT to evaluate tumour absorbed and non-target absorbed dose.

  3. Number of treatment-related adverse events as assessed by CTCAE v4.0

    Time frame: Up to 3 months after intervention

    Safety, expressed in Common Terminology Criteria for Adverse Events, grade 3 and higher, probably or definitely related to the implantation procedure or medical device implant is monitored up to 3 months after intervention.

  4. Tumor response by RECIST 1.1

    Time frame: At 3 months after intervention

    Tumor response to the intervention is evaluated according to the Response evaluation criteria in solid tumors (RECIST) version 1.1 after 3 months.

Sponsors and collaborators

Lead sponsor

Radboud University Medical Center

Other

Collaborators

  • Quirem Medical B.V.

Registry information

Official study title

Intratumoral Holmium Microspheres Brachytherapy for Patients With Pancreatic Cancer; a Single Center, Non-randomized, Feasibility Study in an Open Surgical Setting - the SLOTH1 Study

Acronym: SLOTH-1

Important dates

Study start
2021
Primary completion
2024
Study completion
2024
First posted
Jan 13, 2022
Registry last updated
Apr 11, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.